4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010777
Director sold 67,000 shares at an average $23.36 ($1,564,812)
- Director acquired 67,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ballal Rahul D. Director | 2024-04-10 | Option exercise 10b5-1 | +13,600 | $12.60 | $171,360 | 35,941 | D |
| Ballal Rahul D. Director | 2024-04-10 | Sale 10b5-1 | −13,600 | $21.01 | $285,744 | 22,341 | D |
| Ballal Rahul D. Director | 2024-04-11 | Option exercise 10b5-1 | +48,820 | $12.60 | $615,132 | 71,161 | D |
| Ballal Rahul D. Director | 2024-04-11 | Option exercise 10b5-1 | +4,580 | $19.68 | $90,134 | 75,741 | D |
| Ballal Rahul D. Director | 2024-04-11 | Sale 10b5-1 | −30,300 | $23.14 | $701,024 | 45,441 | D |
| Ballal Rahul D. Director | 2024-04-11 | Sale 10b5-1 | −20,032 | $25.00 | $500,702 | 25,409 | D |
| Ballal Rahul D. Director | 2024-04-11 | Sale 10b5-1 | −3,068 | $25.21 | $77,342 | 22,341 | D |
| Derivatives | |||||||
| Ballal Rahul D. Director | 2024-04-10 | Option exercise · Stock Option (right to buy) 10b5-1 | −13,600 | 48,820 | D | ||
| Ballal Rahul D. Director | 2024-04-11 | Option exercise · Stock Option (right to buy) 10b5-1 | −48,820 | 0 | D | ||
| Ballal Rahul D. Director | 2024-04-11 | Option exercise · Stock Option (right to buy) 10b5-1 | −4,580 | 75,742 | D | ||
| Open-market sales · 67,000 sh · avg $23.36 · $1,564,812 | |||||||
Loading xslF345X05/form4-04122024_100442.xml…